M
Malcolm K. Brenner
Researcher at Center for Cell and Gene Therapy
Publications - 632
Citations - 50064
Malcolm K. Brenner is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 109, co-authored 606 publications receiving 45233 citations. Previous affiliations of Malcolm K. Brenner include St. Jude Children's Research Hospital & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Comparison of the Efficiency of Transduction of Leukemic Cells by Fiber-Modified Adenoviruses
Patricia Yotnda,Patricia Yotnda,C. Zompeta,C. Zompeta,Helen E. Heslop,Michael Andreeff,Malcolm K. Brenner,Frank C. Marini +7 more
TL;DR: Which of these fiber-modified adenovectors is most effective at modifying human primary leukemia cells, and lines is determined.
Journal ArticleDOI
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication
Nicholas K. Foreman,Donna Rill,Donna Rill,Elaine Coustan-Smith,Elaine Coustan-Smith,Edwin C. Douglass,Edwin C. Douglass,Malcolm K. Brenner +7 more
TL;DR: It is found that LFA-3 (CD58), the ligand for CD2 is of predominant importance in predicting susceptibility of neuroblastoma to the cytotoxic actions of NK and LAK cells, while expression of ICAM-1 (CD54) may also modify susceptibility.
Journal ArticleDOI
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
R. Lamba,George Carrum,G.D. Myers,Catherine M. Bollard,Robert A. Krance,Helen E. Heslop,Malcolm K. Brenner,Uday Popat +7 more
TL;DR: Recurrence of CMV infection occurred only in the patients who failed to generate a CTL response to the virus, and recipients of SCT using Alemtuzumab-RIC are initially profoundly immunosuppressed and have a high incidence of early CMV reactivation.
Journal ArticleDOI
Engineering Human Tumor-specific Cytotoxic T Cells to Function in a Hypoxic Environment
Hong-Sung Kim,Guangyong Peng,John Hicks,Heidi L. Weiss,Erwin G. Van Meir,Malcolm K. Brenner,Patricia Yotnda +6 more
TL;DR: HRE-IL-2-modified cytotoxic T lymphocytes (CTLs) produce faster and more complete tumor regression than parental CTLs and increase overall survival and Hypoxia-resistant T cells may thus be of value in the treatment of human tumors in which areas of hypoxia may otherwise account for resistance to this therapeutic strategy.
Journal ArticleDOI
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy
Yuriko Fujita,Ann M. Leen,Jiali Sun,Yozo Nakazawa,Eric Yvon,Helen E. Heslop,Malcolm K. Brenner,Cliona M. Rooney +7 more
TL;DR: A modified rapid selection method for production and characterization of CD4+ and CD8+ T cells specific for cytomegalovirus, Epstein-Barr virus, and adenovirus in a single infusate is described.